Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106914 | 0.79 | CTSC (0.42) | — | |
| SCHEMBL24814613 | 0.75 | DGAT1 (0.50) | POLBMEN1KMT2A | |
| SCHEMBL14893926 | 0.73 | — | — | |
| SCHEMBL12666587 | 0.71 | MEN1 (0.59) | POLBMEN1KMT2A | |
| SCHEMBL25755229 | 0.67 | CA2 (0.40) | POLBMEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL14904840 | 0.67 | CTSL (0.43) | POLBMEN1KMT2ACA2 | |
| SCHEMBL2722431 | 0.65 | CA2 (0.39) | POLBMEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL21177433 | 0.65 | MEN1 (0.58) | POLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5568383 | 0.65 | CTSS (0.36) | — | |
| SCHEMBL23957778 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3884940-A1 | NOVEL IMIDAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| EP-3884940-A1 | NOVEL IMIDAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| CN-112996505-A | Novel imidazole derivatives | 大正制药株式会社 | 2021-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | SLC11A2, MLX, LPXN | POLB 3819/4885MEN1 3530/4885KMT2A 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.